Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Lopes, Luciane Cruz ^a   Spencer, Frederick A ^b   Neumann, Ignacio ^b,c   Ventresca, Matthew ^b   Ebrahim, Shanil ^b,d   Zhou, Qi ^b   Bhatnagar, Neera ^b   Schulman, Sam ^b   Eikelboom, John ^b   Guyatt, Gordon ^b  

^a UNIVERSITY OF SOROCABA   (Brazil)

^b MCMASTER UNIVERSITY   (Canada)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; PLACEBO;

AGE DISTRIBUTION; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL DECISION MAKING; COHORT ANALYSIS; ETHNIC DIFFERENCE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; LONGITUDINAL STUDY; NURSE PATIENT RATIO; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEX DIFFERENCE; SYSTEMATIC REVIEW;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; VITAMIN K;

EID: 84895560449     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088131     Document Type: Article

References (39)

1. Lopes LC, Spencer FA, Neumann I, Ventresca M, Ebrahim S, et al. (2013) Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: Systematic review and meta-analysis. Clin Pharmacol Ther.
2. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, et al. (2012) Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e531S-575S.
3. Meiltz A, Zimmermann M, Urban P, Bloch A, Association of Cardiologists of the Canton of G (2008) Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace 10: 674-680. (Pubitemid 351775267)
4. Lee BH, Park JS, Park JH, Park JS, Kwak JJ, et al. (2010) The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. Journal of Cardiovascular Electrophysiology 21: 501-507.
5. Ruiz Ortiz M, ?Romo E,?Mesa D,?Delgado M, Anguita M, et al. (2010) Oral anticoagulation in nonvalvular atrial fibrillation in clinical practice: Impact of CHADS2 score on outcome. Cardiology 115: 200-204.
6. Leung CS, Tam KM (2003) Antithrombotic treatment of atrial fibrillation in a regional hospital in Hong Kong. Hong Kong Medical Journal 9: 179-185. (Pubitemid 36644582)
7. Parkash R, Wee V, Gardner MJ, Cox JL, Thompson K, et al. (2007) The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Canadian Journal of Cardiology 23: 457-461. (Pubitemid 46978001)
8. SPAF (1998) Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 279: 1273-1277.
9. Lai HM, Aronow WS, Kalen P, Adapa S, Patel K, et al. (2009) Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. International Journal of Nephrology and Renovascular Disease 2.
10. Boulanger L, Hauch O, Friedman M, Foster T, Dixon D, et al. (2006) Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation. Annals of Pharmacotherapy 40: 1024-1029. (Pubitemid 43890902)
11. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, et al. (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138: 1093-1100.
12. Burton C, Isles C, Norrie J, Hanson R, Grubb E (2006) The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study. British Journal of General Practice 56: 697-702. (Pubitemid 44390244)
13. Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O (2005) Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Current Medical Research & Opinion 21: 1583-1594. (Pubitemid 41509186)
14. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, et al. (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170: 1433-1441.
15. Jackson SL, Peterson GM, Vial JH, Daud R, Ang SY (2001) Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Internal Medicine Journal 31: 329-336. (Pubitemid 34225186)
16. Currie CJ, Jones M, Goodfellow J, McEwan P, Morgan CL, et al. (2006) Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. Heart 92: 196-200. (Pubitemid 43131960)
17. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, et al. (2006) Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). American Heart Journal 151: 713-719. (Pubitemid 43290267)
18. Boccuzzi SJ, Martin J, Stephenson J, Kreilick C, Fernandes J, et al. (2009) Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed. Current Medical Research and Opinion 25: 2853-2864.
19. Sam C, Massaro JM, D'Agostino RB Sr, Levy D, Lambert JW, et al. (2004) Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). American Journal of Cardiology 94: 947-951. (Pubitemid 39349566)
20. Shen AY-J, Yao JF, Brar SS, Jorgensen MB, Chen W (2007) Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. Journal of the American College of Cardiology 50: 309-315. (Pubitemid 47061504)
21. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, et al. (2009) The net clinical benefit of warfarin anticoagulation in atrial fibrillation.[Summary for patients in Ann Intern Med. 2009 Sep 1;151(5):I36; PMID: 19721014]. Annals of Internal Medicine 151: 297-305.
22. Wess ML, Schauer DP, Johnston JA, Moomaw CJ, Brewer DE, et al. (2008) Application of a decision support tool for anticoagulation in patients with nonvalvular atrial fibrillation. Journal of General Internal Medicine 23: 411-417. (Pubitemid 351467628)
23. Friberg L, Hammar N, Rosenqvist M (2010) Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. European Heart Journal 31: 967-975.
24. AFASAK (1989) Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen study. Lancet 333 (8631): 175-179.
25. BAATF (1990) Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med 323: 1505-1511.
26. Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, et al. (2006) Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke 37: 447-451. (Pubitemid 43732003)
27. Edvardsson N, Juul-Moller S, Omblus R, Pehrsson K (2003) Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. J Intern Med 254: 95-101. (Pubitemid 36819134)
28. EAFT (1993) Secundary preventionin non-rheumatic atrial fibrillation after transient ischemick attack or minor stroke. Lancet 342: 1255-1262.
29. CAFA, Connolly SJ, Laupacis A, Gent M, Roberts RS, et al. (1991) Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am CollCardiol 18: 349-355.
30. SPINAF, Ezekowitz MD, Bridgers SL, James KE, Carliner NH, et al. (1992) Warafarin in the preventin of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 327: 1406-1412.
31. AFI (1994) Atrial Fibrillation Investigators: Atrial Fibrillation, Aspirin, Anticoagulation Study, Boston Area Anticoagulation Trial for Atrial Fibrillation Study, Canadian Atrial Fibrillation Anticoagulation Study, Stroke Prevention in Atrial Fibrillation Study, Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study,Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation: Analysis of Pooled Data From Five Randomized Controlled Trials. Arch Intern Med 154: 1449-1457.
32. SPAF (1991) Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 84: 527-539.
33. Hu DY, Zhang HP, Sun YH, Jiang LQ (2006) [The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. Zhonghua Xin Xue Guan Bing Za Zhi 34: 295-298.
34. Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, et al. (1997) Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 28: 1015-1021. (Pubitemid 27209152)
35. NASPEAF (2004) Comparative Effects of Antiplatelet, Anticoagulant, or Combined Therapy in Patients With Valvular and Nonvalvular Atrial Fibrillation. J Am Coll Cardiol 44: 1557-1566.
36. SPAFII (1994) Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 343: 687-691.
37. AFASAK 2, Gullov AL, Koefoed BG, Petersen P (1999) Bleeding During Warfarin and Aspirin Therapy in Patients With Atrial Fibrillation: The AFASAK 2 Study. Arch Intern Med 159: 1322-1328.
38. PATAF, Hellemons BSP, Langenberg M, Lodder J, Vermeer F, et al. (1997) Primary prevention of arterial thromboembolism in patients with nonrheumatic atrial fibrillation in general practice (the PATAF study). Cerebrovascular Diseases 7: 11.
39. BAFTA (2007) Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fi brillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370: 493-503.